Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Dietary patterns to mitigate genetic risk of obesity.

Schwenke DC.

Curr Opin Lipidol. 2019 Aug;30(4):351-352. doi: 10.1097/MOL.0000000000000617. No abstract available.

PMID:
31290812
2.

Dietary patterns to reduce mortality and promote independent functioning.

Schwenke DC.

Curr Opin Lipidol. 2019 Jun;30(3):256-257. doi: 10.1097/MOL.0000000000000595. No abstract available.

PMID:
31045607
3.

Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.

Zhou JJ, Schwenke DC, Bahn G, Reaven P; VADT Investigators.

Diabetes Care. 2018 Oct;41(10):2187-2194. doi: 10.2337/dc18-0548. Epub 2018 Aug 6.

4.

Paths to progress on protective dietary patterns.

Schwenke DC.

Curr Opin Lipidol. 2018 Aug;29(4):355-356. doi: 10.1097/MOL.0000000000000530. No abstract available.

PMID:
29994841
5.

Optimizing dietary patterns to decrease premature mortality.

Schwenke DC.

Curr Opin Lipidol. 2017 Aug;28(4):381-382. doi: 10.1097/MOL.0000000000000437. Review. No abstract available.

PMID:
28700379
6.

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.

Saremi A, Howell S, Schwenke DC, Bahn G, Beisswenger PJ, Reaven PD; VADT Investigators.

Diabetes Care. 2017 Apr;40(4):591-598. doi: 10.2337/dc16-1875. Epub 2017 Feb 1.

7.

Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.

Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N.

Age (Dordr). 2016 Dec;38(5-6):485-493. doi: 10.1007/s11357-016-9946-6. Epub 2016 Sep 1.

8.

Increasing dietary fruits and vegetables to reduce healthcare costs.

Schwenke DC.

Curr Opin Lipidol. 2016 Aug;27(4):422-3. doi: 10.1097/MOL.0000000000000323. No abstract available.

PMID:
27383282
9.

Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study.

Dev S, Hoffman TK, Kavalieratos D, Heidenreich P, Wu WC, Schwenke DC, Tracy SJ.

J Am Heart Assoc. 2016 Mar 31;5(3):e002493. doi: 10.1161/JAHA.115.002493.

10.

Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA.

J Clin Endocrinol Metab. 2016 May;101(5):2056-62. doi: 10.1210/jc.2015-4202. Epub 2016 Mar 16.

11.

Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.

Koska J, Yassine H, Trenchevska O, Sinari S, Schwenke DC, Yen FT, Billheimer D, Nelson RW, Nedelkov D, Reaven PD.

J Lipid Res. 2016 May;57(5):894-905. doi: 10.1194/jlr.P064816. Epub 2016 Mar 3.

12.

Improving dietary quality by increasing plant foods when income is limited.

Schwenke DC.

Curr Opin Lipidol. 2015 Oct;26(5):465-7. doi: 10.1097/MOL.0000000000000222. No abstract available.

PMID:
26339768
13.

Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD.

Belalcazar LM, Lang W, Haffner SM, Schwenke DC, Kriska A, Balasubramanyam A, Hoogeveen RC, Pi-Sunyer FX, Tracy RP, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Research Group.

Diabetes Care. 2015 Aug;38(8):1544-50. doi: 10.2337/dc14-2775. Epub 2015 May 13.

14.

Designing dietary patterns to minimize overall disease burden.

Schwenke DC.

Curr Opin Lipidol. 2015 Jun;26(3):241-2. doi: 10.1097/MOL.0000000000000187. No abstract available.

PMID:
25950707
15.

Weight Loss Promotes Nonbariatric Surgery Medical Clearance.

Kurtz JL, Bremer AM, Parrington DJ, Schwenke DC.

Fed Pract. 2015 Apr;32(4):20-25.

16.

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.

Koska J, Sands M, Burciu C, D'Souza KM, Raravikar K, Liu J, Truran S, Franco DA, Schwartz EA, Schwenke DC, D'Alessio D, Migrino RQ, Reaven PD.

Diabetes. 2015 Jul;64(7):2624-35. doi: 10.2337/db14-0976. Epub 2015 Feb 26.

17.

A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.

Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA.

J Clin Endocrinol Metab. 2015 May;100(5):1855-62. doi: 10.1210/jc.2014-3824. Epub 2015 Jan 20.

18.

The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial.

Saremi A, Schwenke DC, Bahn G, Ge L, Emanuele N, Reaven PD; VADT Investigators.

Metabolism. 2015 Feb;64(2):218-25. doi: 10.1016/j.metabol.2014.10.010. Epub 2014 Oct 17.

19.

Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.

Belalcazar LM, Anderson AM, Lang W, Schwenke DC, Haffner SM, Yatsuya H, Rushing J, Vitolins MZ, Reeves R, Pi-Sunyer FX, Tracy RP, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Research Group.

J Acad Nutr Diet. 2014 Nov;114(11):1800-10.e2. doi: 10.1016/j.jand.2014.06.357. Epub 2014 Aug 15.

20.

Nutrient-rich fruits and vegetables: key for preventing cardiovascular and all-cause mortality in those with pre-existing cardiovascular disease?

Schwenke DC.

Curr Opin Lipidol. 2014 Aug;25(4):317-8. doi: 10.1097/MOL.0000000000000102. No abstract available.

PMID:
25003739
21.

p38α mitogen-activated kinase mediates cardiomyocyte apoptosis induced by palmitate.

Oh CC, Nguy MQ, Schwenke DC, Migrino RQ, Thornburg K, Reaven P.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):628-33. doi: 10.1016/j.bbrc.2014.06.023. Epub 2014 Jun 12.

PMID:
24931668
22.

Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.

Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA.

Diabetes Care. 2014 Jun;37(6):1706-11. doi: 10.2337/dc13-1745. Epub 2014 Apr 4.

23.

Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay.

Oran PE, Trenchevska O, Nedelkov D, Borges CR, Schaab MR, Rehder DS, Jarvis JW, Sherma ND, Shen L, Krastins B, Schwenke DC, Reaven PD, Nelson RW.

PLoS One. 2014 Mar 24;9(3):e92801. doi: 10.1371/journal.pone.0092801. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e95812. Lopez, Mary F [removed].

24.

Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.

Harrington JM, Schwenke DC, Epstein DR, Bailey DE Jr.

Oncol Nurs Forum. 2014 Jan 1;41(1):21-9. doi: 10.1188/14.ONF.21-29.

25.

Focus on fruits and vegetables to reduce cardiovascular disease and all-cause mortality.

Schwenke DC.

Curr Opin Lipidol. 2013 Dec;24(6):526-7. doi: 10.1097/MOL.0000000000000028. No abstract available.

PMID:
24231277
26.

Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk.

Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A; ACT NOW Study.

Diabetes Care. 2013 Nov;36(11):3607-12. doi: 10.2337/dc13-0520. Epub 2013 Sep 23.

27.

Exercise preferences among men with prostate cancer receiving androgen-deprivation therapy.

Harrington JM, Schwenke DC, Epstein DR.

Oncol Nurs Forum. 2013 Sep;40(5):E358-67. doi: 10.1188/13.ONF.E358-E367.

PMID:
23989028
28.

Posttraumatic stress disorder and metabolic syndrome: more questions than answers.

Schwenke DC, Siegel D.

Metab Syndr Relat Disord. 2013 Oct;11(5):297-300. doi: 10.1089/met.2013.1504. Epub 2013 Jul 31. No abstract available.

PMID:
23902133
29.

Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.

Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD; ACT NOW Study.

Diabetes. 2013 Nov;62(11):3920-6. doi: 10.2337/db13-0265. Epub 2013 Jul 17.

30.

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.

Bray GA, Smith SR, Banerji MA, Tripathy D, Clement SC, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Schwenke DC, Stentz FB, Reaven PD, DeFronzo RA.

Diabetes Obes Metab. 2013 Oct;15(10):931-7. doi: 10.1111/dom.12099. Epub 2013 May 7.

PMID:
23551856
31.

Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study.

Belalcazar LM, Haffner SM, Lang W, Hoogeveen RC, Rushing J, Schwenke DC, Tracy RP, Pi-Sunyer FX, Kriska AM, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Research Group.

Obesity (Silver Spring). 2013 May;21(5):944-50. doi: 10.1002/oby.20431.

32.

Plasma concentrations of trans fatty acids in persons with type 2 diabetes between September 2002 and April 2004.

Schwenke DC, Foreyt JP, Miller ER 3rd, Reeves RS, Vitolins MZ; Oxidative Stress Subgroup of the Look AHEAD Research Group.

Am J Clin Nutr. 2013 Apr;97(4):862-71. doi: 10.3945/ajcn.112.046508. Epub 2013 Feb 27.

33.

Beyond the Mediterranean to optimal dietary patterns.

Schwenke DC.

Curr Opin Lipidol. 2013 Feb;24(1):96-100. doi: 10.1097/MOL.0b013e32835c94d2. No abstract available.

PMID:
23298963
34.

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.

Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD.

Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):393-9. doi: 10.1161/ATVBAHA.112.300346. Epub 2012 Nov 21. Erratum in: Arterioscler Thromb Vasc Biol. 2013 May;33(5):e114.

35.

Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study.

Belalcazar LM, Lang W, Haffner SM, Hoogeveen RC, Pi-Sunyer FX, Schwenke DC, Balasubramanyam A, Tracy RP, Kriska AP, Ballantyne CM; Look AHEAD Research Group.

J Lipid Res. 2012 Dec;53(12):2726-33. doi: 10.1194/jlr.M030213. Epub 2012 Sep 5.

36.

Converging on critical dietary components: are specific fruits and vegetables key?

Schwenke DC.

Curr Opin Lipidol. 2012 Feb;23(1):72-5. doi: 10.1097/MOL.0b013e32834f42d9. No abstract available.

PMID:
22241327
37.

Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone.

Paramanandam G, Prommer E, Schwenke DC.

J Palliat Med. 2011 Sep;14(9):1029-33. doi: 10.1089/jpm.2011.0103. Epub 2011 Aug 8.

PMID:
21823925
38.

Nutrition and metabolism--dietary patterns: evidence for the critical importance of vegetables builds.

Schwenke DC.

Curr Opin Lipidol. 2011 Jun;22(3):239-42. doi: 10.1097/MOL.0b013e32834754b3. No abstract available.

PMID:
21562388
39.

Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.

Belalcazar LM, Ballantyne CM, Lang W, Haffner SM, Rushing J, Schwenke DC, Pi-Sunyer FX, Tracy RP; Look Action for Health in Diabetes Research Group.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1689-95. doi: 10.1161/ATVBAHA.111.224386. Epub 2011 Apr 21.

40.

Pioglitazone for diabetes prevention in impaired glucose tolerance.

DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD; ACT NOW Study.

N Engl J Med. 2011 Mar 24;364(12):1104-15. doi: 10.1056/NEJMoa1010949. Erratum in: N Engl J Med. 2011 Jul 14;365(2):189. N Engl J Med. 2011 Sep 1;365(9):869.

41.

A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study.

Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, Schwenke DC, Tracy RP, Pi-Sunyer FX, Ballantyne CM; Look AHEAD Research Group.

Diabetes Care. 2010 Nov;33(11):2297-303. doi: 10.2337/dc10-0728. Epub 2010 Aug 3.

42.

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.

Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD.

Atherosclerosis. 2010 Sep;212(1):217-22. doi: 10.1016/j.atherosclerosis.2010.05.028. Epub 2010 May 25.

PMID:
20557887
43.

Dietary patterns: designs for progress and approaches for health impact.

Schwenke DC.

Curr Opin Lipidol. 2010 Jun;21(3):276-9. doi: 10.1097/MOL.0b013e328339b58c. No abstract available.

PMID:
20463473
44.

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes.

Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD.

Diabetes Care. 2010 May;33(5):1028-30. doi: 10.2337/dc09-1961. Epub 2010 Mar 3.

45.

Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke DC, Stentz FD, Tripathy D; ACT NOW Study Group.

Diabetologia. 2010 Mar;53(3):435-45. doi: 10.1007/s00125-009-1614-2. Epub 2009 Dec 10.

PMID:
20012012
46.

Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study.

Belalcazar LM, Reboussin DM, Haffner SM, Reeves RS, Schwenke DC, Hoogeveen RC, Pi-Sunyer FX, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Obesity, Inflammation, and Thrombosis Research Group.

Diabetes Care. 2010 Jan;33(1):197-9. doi: 10.2337/dc09-1235. Epub 2009 Oct 19.

47.

Dietary patterns: time to simplify the message until we can clarify the specifics.

Schwenke DC.

Curr Opin Lipidol. 2009 Oct;20(5):442-5. doi: 10.1097/MOL.0b013e32833099a4. No abstract available.

PMID:
19741340
48.

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.

Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, Emanuele N, Kayshap M, Marks J, Mudaliar S, Harsha Rao R, Shah JH, Goldman S, Reda DJ, McCarren M, Abraira C, Duckworth W; Veterans Affairs Diabetes Trial.

Diabetes. 2009 Nov;58(11):2642-8. doi: 10.2337/db09-0618. Epub 2009 Aug 3.

49.

The plant protein 'package' may be preferred in high-protein diets.

Schwenke DC.

Curr Opin Lipidol. 2009 Apr;20(2):152-4. doi: 10.1097/MOL.0b013e32832956da. No abstract available.

PMID:
19276896
50.

Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).

Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, Reaven PD; VADT.

Atherosclerosis. 2009 Apr;203(2):610-4. doi: 10.1016/j.atherosclerosis.2008.07.031. Epub 2008 Aug 5.

Supplemental Content

Loading ...
Support Center